The Substance of Approval

FDA records indicate that Par Health USA, LLC's generic version of CellCept, mycophenolate mofetil hydrochloride 500mg/vial intravenous injection, is currently marketed. The FDA approved ANDA 203575 on October 28, 2016, recognizing its bioequivalence and therapeutic equivalence to Roche Holding AG's CellCept intravenous injection. This is a generic drug approval based on the passage of quality and equivalence assessments for off-patent drugs, rather than new clinical results. As a 505(j) ANDA, it was approved without separate Phase 1, 2, or 3 clinical trials or an advisory committee (AdComm) vote.

Drug and Patient Value

Mycophenolate mofetil is a prodrug that is converted to its active metabolite, mycophenolic acid (MPA), and inhibits inosine monophosphate dehydrogenase (IMPDH) I and II, thereby reducing guanosine synthesis and proliferation in T and B cells. It is used in combination with cyclosporine and corticosteroids to prevent organ rejection in kidney, heart, and liver transplant recipients. The injectable formulation is used in early transplant patients who cannot take oral medications. The FDA's initial approval date in the United States was May 3, 1995, and CellCept intravenous injection was approved on August 12, 1998. As a product that expands the formulation options for a well-established standard treatment, its clinical impact is less significant than hospital procurement prices and supply stability in determining patient access.

Market and Competitive Landscape

The global organ transplant immunosuppressant market was valued at $5.9 billion in 2025 and is projected to reach $8.2 billion in 2032. At the time of Par's launch, the 12-month sales of CellCept injectable in the United States were $42 million. Direct competition comes from Roche's CellCept and other generic versions of the same ingredient. In terms of treatment regimens, Astellas Pharma's (4503.T) Prograf (tacrolimus, a calcineurin inhibitor), Novartis' (NVS) Myfortic (mycophenolic acid sodium, an IMPDH inhibitor), cyclosporine, and azathioprine form a competitive and combination axis. For generic injectables, market growth is less dependent on manufacturing costs, aseptic production capacity, and supply disruptions than on hospital bidding. Therefore, while holding the approval is a defensive asset, it does not guarantee exclusive pricing power.

Regulatory History and Risks

In Europe, CellCept received EMA approval on February 14, 1996, and in Japan, the capsule formulation was approved on September 22, 1999, after PMDA review. The U.S. ANDA approval included a mycophenolate Risk Evaluation and Mitigation Strategy (REMS) to manage fetal risks, and in 2025, the U.S. label was updated to include the risk of severe hypersensitivity reactions, anaphylaxis, and angioedema. Par voluntarily recalled one lot, AD812, in 2019 due to the observation of glass particles, and no related adverse events were reported. Given that the FDA issued cGMP warning letters to Par Health USA and Endo USA regarding their aseptic manufacturing facilities in April 2026, the key to investment decisions is not the continuation of the approval, but rather the corrective actions and the continuity of the injectable supply.

Why It Matters

Par Health USA's ANDA 203575 is an already marketed 500mg/vial generic, exposed to the $5.9 billion global organ transplant immunosuppressant market in 2025, but its economic viability is determined more by hospital bidding and manufacturing efficiency than by new clinical value. For researchers and clinicians, the availability of a CellCept equivalent that inhibits IMPDH I and II is important for supporting the continuity of treatment for transplant patients who cannot take oral medications. In the short term, the key variables are the aseptic manufacturing corrections and supply disruptions resulting from the FDA's cGMP warning letter in 2026, and the single-lot recall in 2019 should also be considered in quality control assessments. In the medium to long term, the combination/replacement strategy with Prograf, cyclosporine, and Myfortic, and the price competition among multiple generics, mean that corporate value will be determined more by stable supply and cost control than by sales expansion.